Starling Oncology, Inc. (STLN) · Aug 6, 2026 · Earnings

Starling Oncology raises revenue outlook as capitation grows, but margins deteriorate

Guidance raised — 2026 revenue guide raised to $650–670M from $630–650M

Starling lifted 2026 revenue and gross-profit guidance after 35% growth, though higher medical costs and unchanged EBITDA midpoint temper the upgrade.

The headline upgrade is real, but it is mainly a revenue reset. Starling raised its 2026 revenue range by $20 million at both ends and lifted gross-profit guidance, while free-cash-flow guidance stayed unchanged and the adjusted-EBITDA midpoint remained $4.5 million. That makes this a narrow guidance positive rather than a broad profitability re-rating. (2026 Guidance — Previous / Updated)

MetricQ2 2026Q2 20252026 updated guidePrior guide
Total operating revenue$161.3M$119.8M$650–670M$630–650M
Adjusted EBITDA$0.2M$(4.1)M$2–7M$0–9M
Free cash flow, six months$9.5M$(14.6)M$5–15M$5–15M
Capitated revenue, Q2$28.0M$18.8M——
Medical loss ratio85.5%71.0%80–90% next 12 months—
Cash and equivalents$41.1M———
Long-term debt$79.9M———

Growth is accelerating in the company’s preferred business model. Second-quarter revenue increased 35% year over year and adjusted EBITDA turned slightly positive. 〔0〕 Capitated revenue rose 48.5% to $28.0 million, and management now expects roughly $150 million of capitated revenue for 2026. (Financial Highlights; Segment results — Patient services)

The main offset is worsening medical-cost performance. The capitated medical loss ratio climbed to 85.5% from 71.0%, meaning a larger share of capitated revenue is being consumed by patient-care costs before overhead. Management’s stated 80%–90% range leaves room for further deterioration, so the revenue upgrade does not yet translate into a cleaner margin story. (Financial Highlights; Non-GAAP Financial Measures)

Cash generation improved materially, but the balance sheet remains constrained. Six-month operating cash flow swung to $9.7 million from $(15.2) million, producing $9.5 million of free cash flow, while cash ended at $41.1 million against $79.9 million of long-term debt and total liabilities above assets. (Cash Flow statement; Balance Sheet)

Net read: better than the prior standing outlook, but not a decisive earnings inflection. With no external consensus supplied, the clearest benchmark is the company’s previous guidance: revenue and gross profit were raised, but the EBITDA range narrowed around the same midpoint and free-cash-flow expectations were unchanged. The filing therefore supports a narrowly positive read driven by growth and execution, with medical-cost control still unresolved.

Original filing on SEC EDGAR

More Starling Oncology, Inc. news

Starling Oncology raises revenue outlook as capitation grows, but margins deteriorate | STLN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.